Hospital
DLP Conemaugh Miners Medical Center LLC
DLP Conemaugh Miners Medical Center LLC was paid $1.86M by Medicaid between Jan 2020 and Dec 2024, across 100 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoDLP CONEMAUGH MINERS MEDICAL CENTER LLC
HASTINGS, PA 16646
HASTINGS, PA 16646
33aNPI1184620486assigned 06/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.86M
24GClaims60,610
24DCodes billed100
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#90 of 154
Median peer was paid$2.82M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,544 | $113K | |
| 2021 | 28,827 | $756K | |
| 2022 | 8,418 | $312K | |
| 2023 | 9,998 | $342K | |
| 2024incomplete | 8,823 | $341K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 5,683 | 5,433 | $437K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 1,675 | 1,532 | $246K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 2,299 | 2,180 | $245K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 10% | 2,160 | 2,089 | $191K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.5% | 4,069 | 3,946 | $159K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.2% | 1,662 | 1,617 | $59K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 325 | 306 | $51K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 3,378 | 2,053 | $50K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 440 | 408 | $38K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 2,451 | 2,357 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 775 | 753 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 4,468 | 3,997 | $24K |
88 more codes
| 80053 | Comprehensive metabolic panel | 1.2% | 2,055 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 226 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 1,986 | $20K |
| 80050 | General health panel | <1% | 363 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 584 | $14K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 221 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 311 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,416 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 806 | $11K |
| 80061 | Lipid panel | <1% | 706 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,827 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 115 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 42 | $8K |
| 84703 | <1% | 612 | $7K | |
| 84484 | <1% | 830 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 830 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 697 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $5K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 103 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 303 | $4K |
| 93000 | <1% | 552 | $4K | |
| 84439 | <1% | 493 | $4K | |
| 85730 | <1% | 570 | $4K | |
| 83605 | <1% | 540 | $3K | |
| 83735 | <1% | 536 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 406 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 405 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 87 | $3K |
| 83690 | <1% | 666 | $3K | |
| 83880 | <1% | 120 | $3K | |
| 80076 | <1% | 338 | $3K | |
| 81001 | <1% | 1,008 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 28 | $3K |
| 85027 | <1% | 329 | $2K | |
| 85610 | <1% | 707 | $2K | |
| 82607 | <1% | 160 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 295 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 377 | $2K |
| 84100 | <1% | 389 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 30 | $2K |
| 0012A | <1% | 39 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 379 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 359 | $1K |
| 0011A | <1% | 31 | $1K | |
| 81003 | <1% | 429 | $1K | |
| 87077 | <1% | 172 | $1K | |
| 73610 | <1% | 58 | $1K | |
| 73630 | <1% | 106 | $1K | |
| 87081 | <1% | 185 | $1K | |
| 85652 | <1% | 385 | $1K | |
| 87040 | <1% | 97 | $1K | |
| 84460 | <1% | 120 | $952.20 | |
| 86618 | <1% | 34 | $892.29 | |
| 87186 | <1% | 121 | $867.39 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $852.39 |
| 87807 | <1% | 56 | $848.15 | |
| 85379 | <1% | 94 | $789.05 | |
| 86140 | <1% | 308 | $786.74 | |
| 73130 | <1% | 59 | $691.02 | |
| 73564 | <1% | 25 | $657.19 | |
| 71045 | Radiologic examination, chest; single view | <1% | 102 | $635.58 |
| 93971 | <1% | 12 | $628.23 | |
| 83615 | <1% | 82 | $580.51 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $556.17 |
| 82150 | <1% | 110 | $501.14 | |
| 83721 | <1% | 38 | $476.13 | |
| 82570 | <1% | 61 | $443.79 | |
| 84153 | <1% | 12 | $318.16 | |
| 87184 | <1% | 41 | $298.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 493 | $250.21 |
| 90714 | <1% | 42 | $237.31 | |
| 82043 | <1% | 29 | $214.73 | |
| 82746 | <1% | 15 | $211.68 | |
| 83718 | <1% | 26 | $183.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 458 | $175.64 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 341 | $167.84 |
| 82248 | <1% | 18 | $150.34 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $108.49 |
| 94664 | <1% | 19 | $102.59 | |
| J2704 | Injection, propofol, 10 mg | <1% | 280 | $87.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 195 | $58.60 |
| 94760 | <1% | 63 | $47.47 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 28 | $43.52 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 146 | $43.29 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $42.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 345 | $41.47 |
| 82948 | <1% | 16 | $20.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 42 | $9.23 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.